Tango Therapeutics, Inc. is a Boston-based, clinical-stage precision oncology company that develops therapies targeting the genetic concept of synthetic lethality, led by its PRMT5 inhibitors vopimetostat (TNG462) and TNG456 for pancreatic and lung cancers.
The $48 central target is calculated from 11 individually verified analyst price targets spanning roughly $24 to $69. The highest, at $69, comes from Leerink Partners (Andrew Berens, June 2026), while the lowest, at $24, comes from Piper Sandler (Hold), the only non-bullish rating in the group. In between sit targets from H.C. Wainwright ($68), Jefferies ($60, upgraded to Buy in June 2026), Stifel ($55, raised from $40 in October 2026), William Blair ($42, initiated October 2026), J.P. Morgan and Canaccord Genuity ($46 each), Mizuho ($40), Wedbush ($39), and Guggenheim ($35).
The dispersion is telling. Bullish analysts emphasize the scale of the pancreatic ductal adenocarcinoma (PDAC) opportunity, with Stifel citing peak sales potential near $7.1 billion after updated vopimetostat/daraxonrasib data and FDA alignment on a Phase 3 first-line PDAC trial. Piper Sandler's far lower $24 target reflects caution about valuation and execution. No single target should be treated as a guarantee; the mean simply summarizes a wide spectrum of opinion.
Shares of TNGX closed near $23.34, meaning the path to $48 entails a roughly 106% advance — a very large required move by any standard. That magnitude is typical of clinical-stage biotechnology names, where a single regulatory or data catalyst can re-rate a stock rapidly in either direction.
The company remains unprofitable, with a consensus 2026 EPS (earnings per share) estimate around -$1.40 and collaboration revenue expected to keep declining as its partnership matures. The investment case therefore depends almost entirely on clinical data, regulatory alignment, and the eventual commercial potential of its oncology pipeline rather than current earnings.
Several verified factors could underpin upside. The most consequential is FDA alignment on a pivotal Phase 3 first-line PDAC trial, a development Stifel cited in raising its target to $55. Encouraging earlier vopimetostat data — reported objective response rates and median progression-free survival well above historical chemotherapy benchmarks in MTAP-deleted PDAC — supports the bull thesis. The company has also maintained a cash runway extending into 2027, reducing near-term financing pressure. A broad pattern of upward target revisions through 2026, including Jefferies' upgrade to Buy and multiple target increases, points to improving sentiment across the Street.
The obstacles are equally real. Tango is a clinical-stage company burning cash, with no near-term path to profitability. It competes against well-funded rivals including Bristol Myers Squibb, Amgen, and Revolution Medicines in the PRMT5 and PDAC arenas, which could compress the market opportunity. The $24 Piper Sandler target — barely above the current share price — reflects genuine skepticism about valuation after a sharp 2026 rally. Clinical setbacks, regulatory delays, dilution, and sector-wide risk-off moves in biotechnology all rank among the principal risks, and the stock's October decline of roughly 16% in a single session illustrates its volatility.
Shares advanced sharply during 2026 from single-digit levels to a mid-year peak above $30 before pulling back to the low-$20s. Round-number zones around $20 and $25 have emerged as nearby reference points, while the prior high above $30 represents a clear resistance level the stock would need to reclaim on any sustained move toward $48. A stock trading this far from its 52-week low but below its recent peak reflects a market still digesting the pace of the earlier rally.
Analyst price targets typically reflect a roughly 12-month research horizon, though firms vary, and this should not be read as a timing guarantee. Investors should track the next quarterly results and any guidance on cash runway, updates on the Phase 3 PDAC trial design and FDA feedback, new vopimetostat and TNG456 data, analyst target revisions, and competitive readouts from rivals in the PRMT5 and pancreatic cancer space.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like TNGX, such tools can help traders surface shifting momentum, track positions, and identify emerging trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals page to see how these signals fit into your own workflow.
Whether TNGX can reach $48 hinges on whether clinical and regulatory catalysts continue to land favorably. The $48 figure — the average of 11 analyst targets — implies a very large, roughly 106% advance from current levels, and the $24-to-$69 spread underscores how divided even bullish analysts are about valuation and execution. FDA alignment on a pivotal pancreatic cancer program and encouraging vopimetostat data form the core of the bull case; unprofitability, competition, and clinical risk form the core of the bear case. The outcome will likely be determined by data, not by the consensus itself.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TNGX has been loosely correlated with AXON. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TNGX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To TNGX | 1D Price Change % | ||
|---|---|---|---|---|
| TNGX | 100% | -16.43% | ||
| AXON - TNGX | 41% Loosely correlated | +1.39% | ||
| IDYA - TNGX | 39% Loosely correlated | -3.90% | ||
| BNTC - TNGX | 36% Loosely correlated | -1.93% | ||
| ORMP - TNGX | 36% Loosely correlated | +0.24% | ||
| RCUS - TNGX | 35% Loosely correlated | -4.24% | ||
More | ||||